The fragmentation of rest/activity cycles in Alzheimer's disease

1995 ◽  
Vol 10 (4) ◽  
pp. 299-304 ◽  
Author(s):  
Laura Ghali ◽  
Robert W. Hopkins ◽  
Peter Rindlisbacher
1998 ◽  
Vol 87 (1) ◽  
pp. 331-339 ◽  
Author(s):  
Girardin Jean-Louis ◽  
Ferdinand Zizi ◽  
Hans Von Gizycki ◽  
Harvey Taub

Dementia has been associated with circadian rhythm disturbances expressed in several dimensions including body temperature, hormonal concentrations, sleep and wakefulness patterns, and rest-activity cycles. These disturbances may be the result of a dampening in the amplitude of the circadian rhythm. One of the symptoms associated with the aging process has been a decline in the amplitude of the melatonin rhythm. Here, the results of melatonin administration to two patients with Alzheimer's disease are presented. Melatonin administration enhanced and stabilized the circadian rest-activity rhythm in one of the patients along with some reduction of daytime sleepiness and an improvement in mood. The other patient, who was characterized by less cognitive impairment, showed no significant changes associated with melatonin ingestion. Interestingly, the acrophase of rest-activity was delayed for about one hour in both patients. These results suggest that melatonin may have beneficial effects in some patients with Alzheimer's disease


2006 ◽  
Vol 22 (4) ◽  
pp. 267-272 ◽  
Author(s):  
Erik Scherder ◽  
Dirk Knol ◽  
Marie-Jose van Tol ◽  
Eus van Someren ◽  
Jan-Berend Deijen ◽  
...  

2003 ◽  
Vol 17 (2) ◽  
pp. 101-108 ◽  
Author(s):  
Erik Scherder ◽  
Dirk Knol ◽  
Eus van Someren ◽  
Jan-Berend Deijen ◽  
Rob Binnekade ◽  
...  

Objective. In previous studies, cranial electrostimulation (CES) had positive effects on sleep in depressed patients and in patients with vascular dementia. The present study examined the effects of low-frequency CES on the rest-activity rhythm and cortisol levels of patients with probable Alzheimer's disease (AD). Method. It was hypothesised that a decreased level of cortisol would parallel a positive effect of low-frequency CES on nocturnal restlessness. Sixteen AD patients were randomly assigned to an experimental group (n = 8) or a control group (n = 8). The experimental group was treated with CES, whereas the control group received sham stimulation, for 30 minutes a day, during 6 weeks. The rest-activity rhythm was assessed by actigraphy. Cortisol was measured repeatedly in the saliva throughout the day by means of salivette tubes. Results. Low-frequency CES did not improve the rest-activity rhythm in AD patients. Moreover, both groups showed an increase instead of a decrease in the level of cortisol. Conclusions: These preliminary results suggest that low-frequency CES has no positive effect on the rest-activity rhythm in AD patients. An alternative research design with high-frequency CES in AD is discussed.


1998 ◽  
Vol 11 (1) ◽  
pp. 7-10 ◽  
Author(s):  
Jerome A. Yesavage ◽  
Leah Friedman ◽  
Helena C. Kraemer ◽  
Art Noda ◽  
Deryl Wicks ◽  
...  

This article reports cross-sectional and follow-up data with actigraphic measures of nocturnal sleep and rest/activity in 61 Alzheimer's disease (AD) patients as well as the relation of actigraphic measures to levels of behavioral disturbance across different stages of the disease. Over the course of approximately 1.5 years' follow-up, patients showed significant deterioration of nocturnal sleep parameters, but no significant change in rest/activity circadian rhythm parameters. There were also significant correlations among nocturnal sleep, rest/activity circadian rhythm, and behavioral disturbance measures, but only in relatively early stages of AD. It is argued that study of nocturnal sleep and circadian rhythm in relation to behavioral disturbance in AD requires longitudinal data and analyses that take into account the stage of disease at which patients are assessed.


2005 ◽  
Vol 9 (05) ◽  
pp. 507 ◽  
Author(s):  
Egemen Savaskan ◽  
Corina Schnitzler ◽  
Carmen Schröder ◽  
Christian Cajochen ◽  
Franz Müller-Spahn ◽  
...  

2021 ◽  
Author(s):  
Helen Wong ◽  
Jordan M. Buck ◽  
Curtis Borski ◽  
Jessica Pafford ◽  
Bailey N. Keller ◽  
...  

Abstract Background: Regulator of calcineurin 1 (RCAN1) is overexpressed in Down syndrome (DS), but RCAN1 levels are also increased in Alzheimer's disease (AD) and normal aging. AD is highly comorbid among individuals with DS and is characterized in part by progressive neurodegeneration that resembles accelerated aging. Importantly, abnormal RCAN1 levels have been demonstrated to promote memory deficits and pathophysiology symptomatic of DS, AD, and aging. Anomalous diurnal rest-activity patterns and circadian rhythm disruptions are also common in DS, AD, and aging and have been implicated in facilitating age-related cognitive decline and AD progression. However, no prior studies have assessed whether RCAN1 dysregulation may also promote the age-associated alteration of rest-activity profiles and circadian rhythms, which could in turn contribute to neurodegeneration in DS, AD, and aging. Methods: The present study examined the impacts of RCAN1 deficiency and overexpression on the photic entrainment, circadian periodicity, intensity and distribution, diurnal patterning, and circadian rhythmicity of wheel running in young (3-6 months old) and aged (9-14 months old) mice. All data were initially analyzed by multifactorial ANOVA with variables of genotype, age, treatment, and sex considered as dependent variables.Results: We found that daily RCAN1 levels in the hippocampi of light-entrained young mice are generally constant and that balanced RCAN1 expression is necessary for normal circadian locomotor activity rhythms. While the light-entrained diurnal period was unaltered, RCAN1-null and -overexpressing mice displayed lengthened endogenous (free-running) circadian periods like mouse models of AD and aging. In light-entrained young mice, RCAN1 knockout and overexpression also recapitulated the general hypoactivity, diurnal rest-wake pattern fragmentation, and attenuated amplitudes of circadian activity rhythms reported in DS, preclinical and clinical AD, healthily aging individuals, and rodent models thereof. Under constant darkness, RCAN1-null and -overexpressing mice displayed altered locomotor behavior indicating circadian clock dysfunction. Using the Dp(16)1Yey/+ (Dp16) mouse model for DS, which expresses three copies of Rcan1, we found reduced wheel running activity and rhythmicity in both light-entrained and free-running young Dp16 mice like young RCAN1-overexpressing mice. Critically, these diurnal and circadian deficits were rescued in part or entirely by restoring Rcan1 to two copies in Dp16 mice. Conclusions: Collectively, this study's findings suggest that both loss and aberrant gain of RCAN1 precipitate anomalous light-entrained diurnal and circadian activity patterns emblematic of DS, AD, and aging.


2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Adriano Targa ◽  
Ivan David Benitez ◽  
Faride Dakterzada ◽  
John Fontenele Araujo ◽  
Olga Minguez ◽  
...  

SLEEP ◽  
2020 ◽  
Vol 43 (11) ◽  
Author(s):  
Mikolaj J Filon ◽  
Eli Wallace ◽  
Samantha Wright ◽  
Dylan J Douglas ◽  
Lauren I Steinberg ◽  
...  

Abstract Study Objectives Accumulating evidence suggests a strong association between sleep, amyloid-beta (Aβ) deposition, and Alzheimer’s disease (AD). We sought to determine if (1) deficits in rest-activity rhythms and sleep are significant phenotypes in J20 AD mice, (2) metabotropic glutamate receptor 5 inhibitors (mGluR5) could rescue deficits in rest-activity rhythms and sleep, and (3) Aβ levels are responsive to treatment with mGluR5 inhibitors. Methods Diurnal rest-activity levels were measured by actigraphy and sleep-wake patterns by electroencephalography, while animals were chronically treated with mGluR5 inhibitors. Behavioral tests were performed, and Aβ levels measured in brain lysates. Results J20 mice exhibited a 4.5-h delay in the acrophase of activity levels compared to wild-type littermates and spent less time in rapid eye movement (REM) sleep during the second half of the light period. J20 mice also exhibited decreased non-rapid eye movement (NREM) delta power but increased NREM sigma power. The mGluR5 inhibitor CTEP rescued the REM sleep deficit and improved NREM delta and sigma power but did not correct rest-activity rhythms. No statistically significant differences were observed in Aβ levels, rotarod performance, or the passive avoidance task following chronic mGluR5 inhibitor treatment. Conclusions J20 mice have disruptions in rest-activity rhythms and reduced homeostatic sleep pressure (reduced NREM delta power). NREM delta power was increased following treatment with a mGluR5 inhibitor. Drug bioavailability was poor. Further work is necessary to determine if mGluR5 is a viable target for treating sleep phenotypes in AD.


Sign in / Sign up

Export Citation Format

Share Document